

Bariatric surgery effects on glycemic control and diabetes mellitus remission: A meta-analysis

To Cite:

Mirghani H, Alamrani B, Algabri M, Alatawi M, Alasmari M, Alsharif A, Alqahtani F, Albalawi M, Alamrani F, Albalawi A, Alalawi A. Bariatric surgery effects on glycemic control and diabetes mellitus remission: A meta-analysis. *Medical Science* 2022; 26: ms510e2603.

doi: <https://doi.org/10.54905/disssi/v26i130/ms510e2603>

Authors' Affiliation:

¹Professor of Internal Medicine and Endocrine, Medical Department, Faculty of Medicine, University of Tabuk, KSA

²Faculty of Medicine, University of Tabuk, Saudi Arabia

***Corresponding author**

Faculty of Medicine, University of Tabuk, Saudi Arabia

Email: 341000690@stu.ut.edu.sa

Peer-Review History

Received: 16 November 2022

Reviewed & Revised: 18/November/2022 to 28/November/2022

Accepted: 29 November 2022

Published: 02 December 2022

Peer-review Method

External peer-review was done through double-blind method.

URL: <https://www.discoveryjournals.org/medicalscience>



This work is licensed under a Creative Commons Attribution 4.0 International License.

Hyder Mirghani¹, Bandar Alamrani^{2*}, Mohammad Algabri², Meshal Alatawi², Mohammed Alasmari², Ali Alsharif², Fahad Alqahtani², Mshari Albalawi², Fadi Alamrani², Asem Albalawi², Ali Alalawi²

ABSTRACT

Introduction: There is an increasing awareness of morbidity-based indications for bariatric surgery, literature on bariatric surgery and diabetes is scarce. **Aim:** We aimed to assess the bariatric surgery role in diabetes remission and HbA1c reduction. **Methods:** We systematically searched three databases Pub Med, Cochrane Library and Google Scholar from the first published article up to September 2022. Two reviewers searched the databases using the following keywords: Diabetes remission, HbA1c level, glycosylated hemoglobin, glycemic control, Bariatric surgery, sleeve gastrectomy and Roux-en-Y gastric bypass. The retrieved data were entered in a datasheet detailing the author's name, year and country of publication, the methodology and HbA1c levels before and after surgery and diabetes remission. The data were analyzed using the most recent RevMan. **Results:** Out of the 12 studies included in the final meta-analysis, five studies on bariatric surgery effect on the glycosylated hemoglobin (5257 events) showed a reduction of the glycosylated hemoglobin (odds ratio, -1.05, 95% CI, -1.15-0.96). A substantial heterogeneity was observed, ($I^2=79%$, P -value=0.0007) the P -value for the overall effect<0.001. Regarding the complete resolution of diabetes mellitus, we pooled seven studies and found a complete resolution of diabetes mellitus following bariatric surgery (odds ratio, 29.25, 95% CI, 10.92-78.43). No heterogeneity was observed, ($I^2=0%$, P -value=0.63). The P -value for overall effect<0.001 and the chi-square=4.32 with a mean difference of 6. **Conclusion:** Bariatric surgery was effective in diabetes remission and improving HbA1c. Further studies comparing different types of bariatric surgery regarding the same are needed.

Keywords: Bariatric surgery, glycemic control, diabetes remission.

1. INTRODUCTION

Under half a billion people are living with diabetes mellitus globally. In addition, the same number is suffering from the disease without awareness of

the diagnosis. The projection is to increase by 25% and 51% by the years 2030 and 2045 respectively (Saeedi et al., 2019). Although dietary management, exercise and antidiabetic medications are the best methods for improving glycemic control however, lifestyle intervention is difficult to follow and antidiabetic medication is not without side effects (Garcia-Molina et al., 2020; Salehi et al., 2019). Furthermore, most patients with diabetes mellitus are not reaching glycemic targets with increasing complications, morbidity and mortality (Phillips and Shikora, 2018).

Bariatric surgery and since 1950 and over the decades showed a meaningful weight reduction and substantial improvement in diabetes control, hypertension and cholesterol as major cardiovascular risk factors. Furthermore, an improvement in the procedure substantially decreased surgical complications despite the high-risk patients undergoing the operation. The evolution from high mortality and morbidity to a laudable safety and the benefits observed on metabolic disorders and independent of weight loss indicated that metabolic surgery may be targeted for various metabolic disorders (Basto-Abreu et al., 2020). There is an increasing awareness about metabolic oriented bariatric surgery regardless of weight management. The neurohormonal modulation inside and outside the gut will be targeted. Duodenal stimulation and terminal ileum bypass showed promising effects (Buchwald et al., 2020). The current meta-analysis aimed to assess the effects of bariatric surgery on diabetes remission and glycated hemoglobin.

2. MATERIALS AND METHODS

Eligibility criteria according to PICOS

Studies were eligible if they were randomized controlled studies, cross-sectional studies, case control and case series were excluded. The trials must be published in English and report the effects of bariatric surgery on diabetes remission or glycated hemoglobin. Animal studies and experimental studies were not included.

Outcome measures

The outcome measures were the diabetes remission and the effects on HbA1c after bariatric surgery.

Literature search and data extraction

A systematic literature search was conducted in PubMed Medline, Cochrane Library and Google Scholar from the date of the first inception up to September 2022. Two reviewers searched the databases for relevant articles. The diabetes remission, HbA1c improvement, glycated hemoglobin, glycemic control, Bariatric surgery, gastric bypass, sleeve gastrectomy and Roux-en-Y gastric bypass were used. The titles, abstracts and references of the included studies were screened. Any discrepancy was solved by a consensus. We identified 1435 studies and 240 stands after the removal of duplication from them, 66 full texts were screened and only 12 studies were included in the final meta-analysis. A datasheet was used to extract the author's name year and country of publication, the study type, HbA1c improvement and diabetes remission. A modified Cochrane risk of bias assessed the quality of the included studies (Higgins et al., 2016) (Tables 1, 2, 3 and Figure 1).

Risk of bias assessment

A modified Cochrane tool was used (Higgins et al., 2016).

Statistical analysis

The most recent version of the RevMan system was used. We pooled 12 cohorts from ten studies (five on HbA1c and seven on diabetes remission). The dichotomous data were entered manually and the random effect was applied for HbA1c outcome due to the significant heterogeneity. No heterogeneity was observed regarding diabetes remission. Thus, the fixed effect was applied. A P-value of <0.05 was considered significant.

Table 1 Bariatric surgery and diabetes remission

Author	Year	Country	Duration	Method	Bariatric	Drugs	P-value
Courcoulas et al., (2014)	2014	USA	1 year	RCT	9/46	0/23	0.0092
Courcoulas et al., (2015)	2015	Spain	3 years	RCT	14/38	0/14	0.04
Courcoulas et al., (2020)	2020	USA	3 years	RCT	20/41	0/20	0.01
Cummings et al., (2016)	2016	USA	1year	RCT	9/15	1/17	0.002
Mingrone et al., (2021)	2021	Italy	10 years	RCT	15/40	1/17	0.04
Parkh et al., (2014)	2014	USA	0.5 years	RCT	13/20	0/24	<0.001




Figure 1 Effects of bariatric surgery on diabetes mellitus (The PRISMA Chart)

Table 2 Bariatric surgery and HbA1c

Author	Year	Country	Duration	Study type	Medical therapy	Bariatric surgery	P-value
Cummings et al., (2016)	2016	USA	1year	RCT	6.9 ± 1.3	6.4 ± 1.6	0.04
Imtaz et al., (2021)	2021	Canada	2 years	RCT	7.8 ± 1.8	6.3 ± 1.2	<0.001
Mingrone et al., (2021)	2012	Italy	2 years	RCT	7.69±0.57	5.65±0.95	<0.001
Parikh et al., (2014)	2014	USA	0.5 years	RCT	7.8 ± 1.7	6.2 ± 0.9	0.0027
Schauer et al., (2012)	2012	USA	1 year	RCT	7.5±1.8	6.5±0.95	0.007

Table 3 Risk of bias of the included randomized controlled trials

Study	Year	Selection	Performance	Attrition	Reporting	Other
Courcoulas et al., (2014)	2014	low	Unclear	Low	Low	Low
Courcoulas et al., (2015)	2015	low	Unclear	Low	Low	Low
Courcoulas et al., (2020)	2020	low	Unclear	Low	Low	Low
Cummings et al., (2016)	2016	Low	unclear	low	Low	Unclear
Mingrone et al., (2021)	2021	Low	Unclear	High	Low	Low
Parkh et al., (2014)	2014	Low	Unclear	High	Low	Low
Imtaz et al., (2021)	2021	low	Unclear	Low	Low	Low
Mingrone et al., (2012)	2012	Low	Unclear	High	Low	Low
Schauer et al., (2012)	2012	Low	Unclear	High	Low	Low

3. RESULTS

Regarding the complete resolution of diabetes mellitus, we pooled six studies (Courcoulas et al., 2014; Courcoulas et al., 2015; Courcoulas et al., 2020; Cummings et al., 2016; Mingrone et al., 2021; Parikh et al., 2014) and found a complete resolution of diabetes mellitus following bariatric surgery (odds ratio, 21.63, 95% CI, 7.47-62.57). No heterogeneity was observed ($I^2=0\%$, P -value=0.88). The P -value for overall effect <0.001 and the chi-square=1.80 with a mean difference of 5 (Figure 2). There were five studies (Cummings et al., 2016; Parikh et al., 2014; Imtiaz et al., 2021; Mingrone et al., 2012; Schauer et al., 2012) on bariatric surgery's effect on the glycated hemoglobin (5257 events); the studies showed a reduction of the glycated hemoglobin indicating improvement of glycemic control (odds ratio, -1.05, 95% CI, -1.15-0.96). A substantial heterogeneity was observed ($I^2=79\%$, P -value=0.0007). The P -value for overall effect <0.001 and the chi-square=19.27 with a mean difference of 4 (Figure 3).




Figure 2 Bariatric surgery and diabetes remission




Figure 3 Bariatric surgery and HbA1c

4. DISCUSSION

In the present meta-analysis, bariatric surgery improved the glycated hemoglobin and induced remission of diabetes, a study that included ten studies (Sheng et al., 2017) found similar results. However, the study included only one trial. Another study of seven randomized trials found similar results (Khorngami et al., 2019). The mechanisms for the remission included a higher GLP-1 and lower GIP, Ghrelin and glucagon (Russel et al., 2020). Other proposed mechanisms are the effects on the gut microbiota diversity (Magouliotis et al., 2017). It is interesting to note that baseline glycated hemoglobin and fasting plasma glucose are associated with a lower remission rate while preoperative fasting plasma C-peptide was associated with a higher chance of remission (Yan et al., 2017). BS results on diabetes remission varied by ethnicity as Asian and Black Americans showed a higher rate of remission at five years compared to other ethnicities (Kim et al., 2020; Admiraal et al., 2012) the effects are not related to baseline body mass index (remission were observed even among patient with BMI<30) (Panunzi et al., 2015; Rubio-Almanza et al., 2019). A meta-analysis showed that the chance of diabetes remission is higher for young patients, with good diabetes control and a short duration of diabetes (Wang et al., 2015).

Roux-en-Y gastric bypass (LRYGB) achieved more diabetes remission at one year. However, no difference was found at 2 to 5 years compared to sleeve gastrectomy (Borgeraas et al., 2020; Madadi et al., 2019). Guraya and Strate, (2020) showed that Laparoscopic Roux-en-Y gastric bypass is similar to sleeve gastrectomy in inducing diabetes remission at five years an observation supported by Sha et al., (2020), Xu et al., (2020) in their meta-analysis assessed diabetes remission and found similar results in both procedures. However, a lower rate of complications and a higher rate of safety were reported for sleeve gastrectomy. Further meta-analyses reported a lower rate of gastroesophageal reflux among gastrectomy patients with no differences in diabetes remission (Sharples and Mahawar, 2020).

In addition, sleeve gastrectomy had a lower rate of ulcers, strictures and obstruction compared to LRYGB (Park et al., 2019). On the other hand, Gu et al., (2020) concluded the superiority of (LRYGB). The above results imply that metabolic surgery is an interesting option for diabetes management (Cresci et al., 2020).

5. CONCLUSION

Bariatric surgery improved glycemic control and induced diabetes remission. Further studies comparing laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass are needed.

Acknowledgement

We thank the Saudi Digital Library for accessing the included data.

Authors' contributions

Hyder Mirghani, the concept and design and data analysis, Bandar Alamrani and Mohammad Algabri searched the literature and drafted the introduction, Meshal Alatawi and Mohammed Alasmari drafted the methods, Ali Alsharif and Fahad Alqahtani drafted the results, Mshari Albalawi, Fadi Alamrani, Asem Albalawi and Ali Alalawi discussed the data. All the authors revised the manuscript critically and approved it before submission.

Ethics approval and consent to participate

Not applicable

Informed consent

Not applicable.

Funding

This study has not received any external funding.

Conflict of interest

The authors declare that there is no conflict of interests.

Data and materials availability

All data sets collected during this study are available upon reasonable request from the corresponding author.

REFERENCES AND NOTES

- Admiraal WM, Celik F, Gerdes VE, Dallal RM, Hoekstra JB, Holleman F. Ethnic differences in weight loss and diabetes remission after bariatric surgery: A meta-analysis. *Diabetes Care* 2012; 35(9):1951-8. doi: 10.2337/dc12-0260
- Basto-Abreu A, Barrientos-Gutierrez T, Rojas-Martinez R, Aguilar-Salinas CA, Lopez-Olmedo N, Cruz-Gongora VDL, Rivera-Dommarco J, Shamah-Levy T, Romero-Martinez M, Barquera S, Lopez-Ridaura R, Hernandez-Avila M, Villalpando S. Prevalencia de diabetes y descontrol glucémico en México: Resultados de la Ensanut 2016 (Prevalence of diabetes and poor glycemic control in Mexico: Results from Ensanut 2016). *Salud Publica Mex* 2020; 62(1):50-59. Spanish. doi: 10.21149/10752
- Borgeraas H, Hofso D, Hertel JK, Hjelmestaeth J. Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Obes Rev* 2020; 21(6):e13011. doi: 10.1111/obr.13011
- Buchwald H, Buchwald JN. Metabolic (Bariatric and Nonbariatric) Surgery for Type 2 Diabetes: A Personal Perspective Review. *Diabetes Care* 2019; 42(2):331-340. doi: 10.2337/dc17-2654
- Courcoulas AP, Belle SH, Neiberg RH, Pierson SK, Eagleton JK, Kalarchian MA, DeLany JP, Lang W, Jakicic JM. Three Year Outcomes of Bariatric Surgery Vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial. *JAMA Surg* 2015; 150(10):931-40. doi: 10.1001/jamasurg.2015.1534
- Courcoulas AP, Gallagher JW, Neiberg RH, Eagleton EB, DeLany JP, Lang W, Pouch S, Gourash W, Jakicic JM. Bariatric Surgery Vs Lifestyle Intervention for Diabetes Treatment: 5 Year Outcomes from a Randomized Trial. *J*

- Clin Endocrinol Metab 2020; 105(3):866–76. doi: 10.1210/clinem/dgaa006
7. Courcoulas AP, Goodpaster BH, Eagleton JK, Belle SH, Kalarchian MA, Lang W, Toledo FG, Jakicic JM. Surgical Vs medical treatments for type 2 diabetes mellitus: A randomized clinical trial. *JAMA Surg* 2014; 149(7):707-15. doi: 10.1001/jamasurg.2014.467
 8. Cresci B, Cosentino C, Monami M, Mannucci E. Metabolic surgery for the treatment of type 2 diabetes: A network metaanalysis of randomized controlled trials. *Diabetes Obes Metab* 2020; 22(8):1378-1387. doi: 10.1111/dom.14045
 9. Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, Bock SN, Landers JT, Kratz M, Foster-Schubert KE, Flum DR. Gastric bypass surgery Vs intensive lifestyle and medical intervention for type2 diabetes: The crossroads randomised controlled trial. *Diabetologia* 2016; 59(5):945-53. doi: 10.1007/s00125-016-3903-x
 10. Garcia-Molina L, Lewis-Mikhael AM, Riquelme-Gallego B, Cano-Ibanez N, Oliveras-Lopez MJ, Bueno-Cavanillas A. Improving type 2 diabetes mellitus glycaemic control through lifestyle modification implementing diet intervention: A systematic review and meta analysis. *Eur J Nutr* 2020; 59(4):1313-1328. doi: 10.1007/s00394-019-02147-6
 11. Gu L, Huang X, Li S, Mao D, Shen Z, Khadaroo PA, Ng DM, Chen P. A meta-analysis of the medium and long-term effects of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass. *BMC Surg* 2020; 20(1):30. doi: 10.1186/s12893-020-00695-x
 12. Guraya SY, Strate T. Surgical outcome of laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass for resolution of type2 diabetes mellitus: A systematic review and meta-analysis. *World J Gastroenterol* 2020; 26(8):865-876. doi: 10.3748/wjg.v26.i8.865
 13. Higgins JP, Savovic J, Page MJ, Strene JA. Revised Cochrane risk of bias tool for randomized trials (ROB2.0) 2016. https://www.unisa.edu.au/contentassets/72bf75606a2b4abcaf7f17404af374ad/rob2-0_indiv_main_guidance.pdf
 14. Imtiaz R, Doumouras AG, Hong D, Anvari M, Shah BR. Long-term impact of bariatric surgery on glycemic control and glucose-lowering therapy for people with type2 diabetes: Population based cohort study. *Surg Obes Relat Dis* 2021; 17(6):1049-1056. doi: 10.1016/j.soard.2021.02.015
 15. Khorgami Z, Shoar S, Saber AA, Howard CA, Danaei G, Sclabas GM. Outcomes of Bariatric Surgery Versus Medical Management for Type2 Diabetes Mellitus: A Meta analysis of Randomized Controlled Trials. *Obes Surg* 2019; 29(3):964-974. doi: 10.1007/s11695-018-3552-x
 16. Kim JH, Pyo JS, Cho WJ, Kim SY. The Effects of Bariatric Surgery on Type2 Diabetes in Asian Populations: A Meta analysis of Randomized Controlled Trials. *Obes Surg* 2020; 30(3):910-923. doi: 10.1007/s11695-019-04257-w
 17. Madadi F, Jawad R, Mousati I, Plaeke P, Hubens G. Remission of Type 2 Diabetes and Sleeve Gastrectomy in Morbid Obesity: A Comparative Systematic Review and Meta analysis. *Obes Surg* 2019; 29(12):4066-4076. doi: 10.1007/s11695-019-04199-3
 18. Magouliotis DE, Tasiopoulou VS, Sioka E, Chatedaki C, Zacharoulis D. Impact of Bariatric Surgery on Metabolic and Gut Microbiota Profile: A Systematic Review and Metaanalysis. *Obes Surg* 2017; 27(5):1345-1357. doi: 10.1007/s11695-017-2595-8
 19. Mingrone G, Panunzi S, Gaetano AD, Guidone C, Iaconelli A, Capristo E, Chamseddine G, Bornstein SR, Rubino F. Metabolic surgery versus conventional medical therapy in patients with type2 diabetes: 10 year follow-up of an openlabel, singlecentrerandomised controlled trial. *Lancet* 2021; 397(10271):293-304. doi: 10.1016/S0140-6736(20)32649-0
 20. Mingrone G, Panunzi S, Gaetano AD, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type2 diabetes. *N Engl J Med* 2012; 366(17):1577-85. doi: 10.1056/NEJMoa1200111
 21. Panunzi S, Gaetano AD, Carnicelli A, Mingrone G. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: Do BMI or procedure choice matter? A meta-analysis. *Ann Surg* 2015; 261(3):459-67. doi: 10.1097/SLA.0000000000000863
 22. Parikh M, Chung M, Sheth S, McMacken M, Zahra T, Saunders JK, Ude-Welcome A, Dunn V, Ogedegbe G, Schmidt AM, Pachter HL. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type2 diabetic patients who do not meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. *Ann Surg* 2014; 260(4):617-22; discussion 622-4. doi: 10.1097/SLA.0000000000000919
 23. Park CH, Nam SJ, Choi HS, Kim KO, Kim DH, Kim JW, Sohn W, Yoon JH, Jung SH, Hyun YS, Lee HL. Korean Research Group for Endoscopic Management of Metabolic Disorder and Obesity. Comparative Efficacy of Bariatric Surgery in the Treatment of Morbid Obesity and Diabetes Mellitus: A Systematic Review and Network Meta Analysis. *Obes Surg* 2019; 29(7):2180-2190. doi: 10.1007/s11695-019-03831-6
 24. Phillips BT, Shikora SA. The history of metabolic and bariatric surgery: Development of standards for patient safety and efficacy. *Metabolism* 2018; 79:97-107. doi: 10.1016/j.metabol.2017.12.010
 25. Rubio-Almanza M, Hervas-Marin D, Camara-Gomez R, Caudet-Esteban J, Merino-Torres JF. Does Metabolic Surgery Lead to Diabetes Remission in Patients with BMI < 30 kg/m²? A Meta analysis. *Obes Surg* 2019; 29(4):1105-1116. doi: 10.1007/s11695-018-03654-x

26. Russel SM, Valle V, Spagni G, Hamilton S, Patel T, Abdukadyrov N, Dong Y, Gangemi A. Physiologic Mechanisms of Type II Diabetes Mellitus Remission Following Bariatric Surgery: A Meta analysis and Clinical Implications. *J Gastrointest Surg* 2020; 24(3):728-741. doi: 10.1007/s11605-019-04508-2
27. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2019; 157:107843. doi: 10.1016/j.diabres.2019.107843
28. Salehi B, Ata A, V Anil Kumar N, Sharopov F, Ramirez-Alarcon K, Ruiz-Ortega A, Ayatollahi SA, Fokou PVT, Kobarfard F, Zakaria ZA, Iriti M, Taheri Y, Martorell M, Sureda A, Setzer WN, Durazzo A, Lucarini M, Santini A, Capasso R, Ostrander EA, Atta-ur-Rahman, Choudhary MI, Cho WC, Sharifi-Rad J. Antidiabetic Potential of Medicinal Plants and Their Active Components. *Biomolecules* 2019; 9(10):551. doi: 10.3390/biom9100551
29. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *N Engl J Med* 2012; 366(17):15 67-76. doi: 10.1056/NEJMoa1200225
30. Sha Y, Huang X, Ke P, Wang B, Yuan H, Yuan W, Wang Y, Zhu X, Yan Y. Laparoscopic Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy for Type 2 Diabetes Mellitus in Nonseverely Obese Patients: A Systematic Review and Meta analysis of Randomized Controlled Trials. *Obes Surg* 2020; 30(5):1660-1670. doi: 10.1007/s11695-019-04378-2
31. Sharples AJ, Mahawar K. Systematic Review and Meta analysis of Randomised Controlled Trials Comparing Long-Term Outcomes of Roux-En-Y Gastric Bypass and Sleeve Gastrectomy. *Obes Surg* 2020; 30(2):664-672. doi: 10.1007/s11695-019-04235-2
32. Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L. The Long-Term Effects of Bariatric Surgery on Type2 Diabetes Remission, Microvascular and Macrovascular Complications and Mortality: A Systematic Review and Meta analysis. *Obes Surg* 2017; 27(10):2724-2732. doi: 10.1007/s11695-017-2866-4
33. Wang GF, Yan YX, Xu N, Yin D, Hui Y, Zhang JP, Han GJ, Ma N, Wu Y, Xu JZ, Yang T. Predictive factors of type2 diabetes mellitus remission following bariatric surgery: Ametaanalysis. *Obes Surg* 2015; 25(2):199-208. doi: 10.1007/s11695-014-1391-y
34. Xu C, Yan T, Liu H, Mao R, Peng Y, Liu Y. Comparative Safety and Effectiveness of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in Obese Elder Patients: A Systematic Review and Meta analysis. *Obes Surg* 2020; 30(9):3408-3416. doi: 10.1007/s11695-020-04577-2
35. Yan W, Bai R, Yan M, Song M. Preoperative Fasting Plasma C-Peptide Levels as Predictors of Remission of Type2 Diabetes Mellitus after Bariatric Surgery: A Systematic Review and Meta analysis. *J Invest Surg* 2017; 30(6):383-393. doi: 10.1080/08941939.2016.1259375